Nevro Corp has been recognized for its differentiated high-frequency SCS offerings and solid sales base. However, the company has faced challenges in recent years, struggling with market share and ...

Nevro Corp. (NYSE:NVRO – Get Free Report) has earned a consensus rating of “Reduce” from the thirteen research firms that are covering the company, Marketbeat reports. Two analysts have rated the ...

Nevro Corp is set to release its Q4 2024 earnings on Mar 4, 2025.The consensus estimate for Q4 2024 revenue is $102.54 million, and the earnings are expected to come in at -$0.79 per share. The ...

Nevro Corp. NVRO reported a loss per share of 64 cents in the fourth quarter of 2024, wider than the year-ago quarter’s loss of 15 cents. The Zacks Consensus Estimate is pegged at a loss per ...

REDWOOD CITY, Calif., March 4, 2025 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

The Redwood City, California-based company said it had a loss of $1.41 per share. Losses, adjusted for one-time gains and costs, came to 64 cents per share. The results surpassed Wall Street ...

REDWOOD CITY, Calif., March 4, 2025 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic ...